Baudax Bio, Inc. (BXRX) News

Baudax Bio, Inc. (BXRX): $0.02

0.00 (7.39%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

F

Add BXRX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#361 of 390

in industry

Filter BXRX News Items

BXRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BXRX News Highlights

  • BXRX's 30 day story count now stands at 2.
  • Over the past 20 days, the trend for BXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about BXRX are BIO and DRUG.

Latest BXRX News From Around the Web

Below are the latest news stories about BAUDAX BIO INC that investors may wish to consider to help them evaluate BXRX as an investment opportunity.

Baudax Bio Announces Corporate Update

Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a

Yahoo | October 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news traders need to know about on Friday!

William White on InvestorPlace | September 29, 2023

Why Is Baudax Bio (BXRX) Stock Up 75% Today?

Although Baudax Bio saw significant interest because of its orphan drug designation, BXRX stock must climb a wall of worry.

Josh Enomoto on InvestorPlace | September 28, 2023

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the tre

Yahoo | September 28, 2023

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be he

Yahoo | September 7, 2023

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par

Yahoo | August 23, 2023

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at

Yahoo | August 17, 2023

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T c

Yahoo | August 16, 2023

Why Is Baudax Bio (BXRX) Stock Up 130% Today?

Although Baudax Bio soared on Friday following its acquisition of Teralmmune, BXRX stock remains an extremely speculative venture.

Josh Enomoto on InvestorPlace | June 30, 2023

Baudax Bio Acquires TeraImmune, Inc.

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology co

Yahoo | June 30, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!